A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist widely prescribed for type 2 diabetes mellitus and obesity, is generally well tolerated but can be associated with gastrointestinal adverse effects and, rarely, pancreatitis. As its use…
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a modern class of medications initially approved for type 2 diabetes mellitus (T2DM) but now also widely used for obesity. Although these drugs offer significant benefits for glycem…
Microglial activation driven by NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) inflammasome signaling exacerbates Alzheimer's disease (AD) pathology through enhanced neuroinflammation and amyloid beta (Aβ) accumulation. Semaglutide (SEM) ha…
AIMS: The aim of this systematic review and meta-analysis was to evaluate the effect of GLP-1RAs on functional walking distance and the risk of major adverse limb events (MALE) or lower extremity amputation (LEA) in people with type 2 diabetes and pe…
In 2024, a comprehensive framework for the screening, diagnosis, and management of metabolic dysfunction-associated steatotic liver disease (MASLD) was incorporated in the EASL-EASD-EASO clinical practice guidelines. However, physicians often face ba…
BACKGROUND: Fixed-dose combination of semaglutide/cagrilintide (CagriSema 2.4 mg/2.4 mg) has demonstrated significant and clinically relevant body weight reductions in adults with overweight or obesity compared with placebo. METHODS: The phase 3a, 68…
Eleven modern size-exclusion chromatography (SEC) columns, including prototype columns designed to minimize non-specific interactions, were systematically evaluated for the analysis of peptides and oligonucleotides. Column physical properties and chr…
Spinal epidural lipomatosis (SEL) is a rare cause of lumbar canal stenosis, typically linked to obesity or corticosteroid use. Severe cases often require decompression. We report a 48-year-old man with chronic low back pain and morbid obesity (153 kg…
OBJECTIVES: To evaluate the quality, reliability, and thematic content of user-generated videos on TikTok concerning glucagon-like peptide-1 (GLP-1) receptor agonists. METHODS: This cross-sectional study analyzed the top 400 most popular videos using…
This report describes a female patient in her 60s with an immune-mediated necrotising myopathy (IMNM) occurring after semaglutide use. She was found to have progressive dysphagia, dysphonia, proximal muscle weakness and creatine kinase elevation over…
Sarcopenia associated with aging is a significant health issue affecting the quality of life in the elderly, yet research on effective treatments remains insufficient. This study aims to investigate the therapeutic effects and mechanisms of Semagluti…
AIMS: This systematic review and meta-analysis evaluated the long-term efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) as adjunctive therapies for individuals with type 1 diabetes (T1D) and overweight or obesity. MATERIALS…
BACKGROUND: Psychotropic medications are associated with serious metabolic adverse effects, which contribute to an increased risk of cardiometabolic comorbidities in patients with severe mental illness (SMI). Several intervention strategies are avail…
BACKGROUND: Abdominoplasty in patients with obesity carries a heightened risk of venous thromboembolism (VTE) due to a proinflammatory and hypercoagulable baseline. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used for weigh…
India is struggling with the twin epidemics of diabetes and weight issues, holding the second position globally in the former and third in the latter. Despite multiple advancements with therapies that offer glycemic control and weight benefits, there…